Orexo ABShs News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.06.21	Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents (PR Newswire)
02.06.21	Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents (PR Newswire)
29.04.21	Orexo Q1 2021 Interim Report (PR Newswire)
29.04.21	Orexo Q1 2021 Interim Report (PR Newswire)
23.03.21	Orexo publishes Annual Report for 2020 (PR Newswire)
10.02.21	Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management (PR Newswire)
10.02.21	Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management (PR Newswire)
05.02.21	Orexo calls for redemption of its outstanding bonds and obtains temporary waiver (PR Newswire)
05.02.21	Orexo calls for redemption of its outstanding bonds and obtains temporary waiver (PR Newswire)
04.02.21	Orexo has successfully issued senior unsecured callable floating rate bonds (PR Newswire)
04.02.21	Orexo has successfully issued senior unsecured callable floating rate bonds (PR Newswire)
01.02.21	Orexo contemplates issue of senior unsecured callable floating rate bonds (PR Newswire)
01.02.21	Orexo contemplates issue of senior unsecured callable floating rate bonds (PR Newswire)
29.01.21	Orexo expects FDA filing of OX124 mid 2022 (PR Newswire)
29.01.21	Orexo expects FDA filing of OX124 mid 2022 (PR Newswire)
28.01.21	Orexo Q4 2020, incl. Full Year Report (PR Newswire)
28.01.21	Orexo Q4 2020, incl. Full Year Report (PR Newswire)
27.01.21	Orexo strengthens IP rights for overdose rescue drug OX124 (PR Newswire)
27.01.21	Orexo strengthens IP rights for overdose rescue drug OX124 (PR Newswire)
30.12.20	Orexo announces new US patent for ZUBSOLV® (PR Newswire)
30.12.20	Orexo announces new US patent for ZUBSOLV® (PR Newswire)
07.12.20	Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe (PR Newswire)
07.12.20	Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe (PR Newswire)
16.11.20	Accenture, Orexo Team to Offer Digital Therapeutics through INTIENT™ Platform (PR Newswire)
04.11.20	Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020 (PR Newswire)
04.11.20	Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020 (PR Newswire)
04.11.20	Orexo Interim Report Q3 2020 (PR Newswire)
04.11.20	Orexo Interim Report Q3 2020 (PR Newswire)
15.10.20	Orexo and Lyfebulb Announce the Winner of the 2020 Innovation Challenge in Substance Use Disorders (PR Newswire)
13.10.20	Orexo´s Nomination Committee for the Annual General Meeting 2021 (PR Newswire)
13.10.20	Orexo´s Nomination Committee for the Annual General Meeting 2021 (PR Newswire)
25.09.20	Invitation - Orexo Digital Therapeutics business update October 1 (PR Newswire)
25.09.20	Invitation - Orexo Digital Therapeutics business update October 1 (PR Newswire)
14.09.20	Orexo commences patent infringement litigation against Sun Pharmaceutical (PR Newswire)
14.09.20	Orexo commences patent infringement litigation against Sun Pharmaceutical (PR Newswire)
09.09.20	Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options (PR Newswire)
01.09.20	Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders (PR Newswire)
10.08.20	Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US (PR Newswire)
10.08.20	Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US (PR Newswire)
16.07.20	Orexo Interim Report Q2 2020 (PR Newswire)
16.07.20	Orexo Interim Report Q2 2020 (PR Newswire)
02.07.20	Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance (PR Newswire)
02.07.20	Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance (PR Newswire)
30.06.20	Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal (PR Newswire)
30.06.20	Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal (PR Newswire)
17.06.20	Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder (PR Newswire)
17.06.20	Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder (PR Newswire)
19.05.20	Report From Orexo AB's Extraordinary General Meeting, 19 May 2020 (PR Newswire)
19.05.20	Report From Orexo AB's Extraordinary General Meeting, 19 May 2020 (PR Newswire)
18.05.20	Orexo and Lyfebulb Partner During Unprecedented Times to Help Those Struggling With Alcohol and Opioid Use Disorders (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Orexo ABShs

Aktien Top/Flop

Meistgelesene Nachrichten